Biotech entity
pharma is the sole category represented across all 1 tracked stories. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.9.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.9. Itaconix appears in 1 tracked Biotech story from March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Profitability Forecast
Management officially announces expectations for a profitable 2026 based on current momentum.
Fiscal Year Start
The company enters the fiscal year projected to reach its first full-year profit.
Record Order Backlog
Itaconix finishes the year with a record level of orders for its bio-based polymers.
Itaconix PLC has announced a positive outlook for 2026, driven by record order momentum and the expectation of achieving its first full year of profitability. The company’s plant-based polymers are seeing increased adoption in consumer and industrial sectors as sustainability mandates tighten globally.
Itaconix is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
